Pending Case

FibroGen, Inc.


FibroGen, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

Contact us to learn more about this lawsuit.

Block & Leviton LLP (, a securities litigation firm representing investors and whistleblowers nationwide, is investigating FibroGen, Inc. (NASDAQ: FGEN) and certain of its officers and directors for potential violations of federal securities laws.

FibroGen is a pharmaceutical company developing Roxadustat, a drug designed to stimulate production of hemoglobin and red blood cells. On November 4, 2019, a former analyst at Kerrisdale Capital Management issued a report questioning the safety of Roxadustat, and calling the Company the next “biotech blow-up.” The report alleged that the company was being “mysteriously unforthcoming” and misleading investors regarding the safety and efficacy of Roxadustat. FibroGen’s share price dropped more than $4.00, or about 10%, in intraday trading.

If you have purchased or otherwise acquired FibroGen securities, and have questions about your legal rights, or possess information relevant to this investigation, you are encouraged to contact attorney Mark Delaney at (617) 398-5600, by email at, or by visiting

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

Contact us to learn more about this lawsuit.

Block & Leviton LLP
155 Federal Street, Suite 400
Boston, MA 02110
  • Mon 9am - 6pm
  • Tues 9am - 6pm
  • Wed 9am - 6pm
  • Thurs 9am - 6pm
  • Fri 9am - 6pm
  • Sat Closed
  • Sun Closed
Powered by RooSites